Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:INDV NASDAQ:KROS NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$40.00+0.9%$34.98$23.42▼$62.58$2.30B0.73646,375 shs529,138 shsINDVIndivior$17.14+2.0%$14.01$7.33▼$17.25N/A0.652.81 million shs5.04 million shsKROSKeros Therapeutics$14.46+0.6%$14.03$9.12▼$72.37$584.05M1.26508,108 shs324,817 shsRXRXRecursion Pharmaceuticals$6.49+3.7%$5.12$3.79▼$12.36$2.54B0.9133.10 million shs23.55 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-2.24%-1.73%+18.64%+34.63%-17.72%INDVIndivior-0.83%+4.02%+20.76%+45.42%+54.50%KROSKeros Therapeutics-0.35%+0.14%+4.89%+1.20%-70.99%RXRXRecursion Pharmaceuticals-2.64%+13.41%+19.92%+9.25%-19.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.3542 of 5 stars3.43.00.04.32.00.81.9INDVIndivior1.1403 of 5 stars1.61.00.00.01.91.71.9KROSKeros Therapeutics2.2103 of 5 stars3.31.00.00.03.33.30.0RXRXRecursion Pharmaceuticals0.7941 of 5 stars1.22.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.75Moderate Buy$57.3343.33% UpsideINDVIndivior 3.20Buy$17.753.56% UpsideKROSKeros Therapeutics 2.50Moderate Buy$30.56111.31% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$7.007.86% UpsideCurrent Analyst Ratings BreakdownLatest KROS, AGIO, RXRX, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025AGIOAgios PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$52.00 ➝ $51.007/22/2025INDVIndiviorJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.007/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.007/3/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$5.006/30/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $22.006/16/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.006/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.005/30/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.005/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.005/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $25.005/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M63.47N/AN/A$27.02 per share1.48INDVIndivior$1.19BN/A$1.86 per share9.23($2.52) per shareN/AKROSKeros Therapeutics$3.55M165.45N/AN/A$14.11 per share1.02RXRXRecursion Pharmaceuticals$58.84M44.84N/AN/A$2.61 per share2.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.56N/AN/A1,798.26%-2.75%-2.52%7/31/2025 (Estimated)INDVIndivior$2M-$0.31N/A10.02N/A-4.02%-97.29%15.74%7/31/2025 (Estimated)KROSKeros Therapeutics-$187.35M-$0.18N/AN/A2.601.96%0.75%0.69%8/6/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.77N/AN/AN/A-961.32%-74.70%-54.02%8/6/2025 (Estimated)Latest KROS, AGIO, RXRX, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.34N/AN/AN/AN/AN/A8/6/2025Q2 2025KROSKeros Therapeutics-$1.13N/AN/AN/A$3.83 millionN/A7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74N/AN/AN/A$9.46 millionN/A7/31/2025Q2 2025INDVIndivior$0.25N/AN/AN/A$239.43 millionN/A5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 million5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93INDVIndiviorN/A0.880.72KROSKeros TherapeuticsN/A19.2919.29RXRXRecursion Pharmaceuticals0.024.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AINDVIndivior60.33%KROSKeros Therapeutics71.56%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%INDVIndiviorN/AKROSKeros Therapeutics20.60%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableINDVIndivior1,051N/AN/ANot OptionableKROSKeros Therapeutics10040.62 million32.25 millionOptionableRXRXRecursion Pharmaceuticals400406.49 million372.23 millionOptionableKROS, AGIO, RXRX, and INDV HeadlinesRecent News About These CompaniesHow Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big PharmaJuly 25 at 1:53 PM | benzinga.comRXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?July 25 at 12:36 PM | zacks.comRecursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to NoteJuly 23 at 6:51 PM | zacks.comCan Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?July 23 at 11:06 AM | zacks.comRecursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 EarningsJuly 22 at 4:54 PM | insidermonkey.comPier 88 Investment Partners LLC Sells 66,940 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)July 22 at 11:41 AM | marketbeat.comBrokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $7.00July 22 at 2:40 AM | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Time to Buy?July 21, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?July 21, 2025 | zacks.comRecursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder HypophosphatasiaJuly 21, 2025 | finance.yahoo.comQ2 Earnings Estimate for RXRX Issued By Leerink PartnrsJuly 21, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Sees 14% Price Surge Over Last MonthJuly 20, 2025 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of "Hold" from AnalystsJuly 19, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9.4% - Here's WhyJuly 18, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key FactsJuly 17, 2025 | zacks.comRecursion Pharmaceuticals Rises 6% in a Month: How to Play the StockJuly 17, 2025 | zacks.comCan Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?July 16, 2025 | zacks.comD.A. Davidson & CO. Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)July 11, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth KnowingJuly 10, 2025 | zacks.comMorgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight RatingJuly 10, 2025 | msn.comRecursion Pharmaceuticals (RXRX) Rallies 8.7% on HypophosphatasiaJuly 9, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKROS, AGIO, RXRX, and INDV Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$40.00 +0.35 (+0.88%) Closing price 04:00 PM EasternExtended Trading$39.99 -0.01 (-0.02%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Indivior NASDAQ:INDV$17.14 +0.33 (+1.96%) Closing price 04:00 PM EasternExtended Trading$17.14 0.00 (-0.03%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Keros Therapeutics NASDAQ:KROS$14.46 +0.08 (+0.56%) Closing price 04:00 PM EasternExtended Trading$14.45 -0.01 (-0.10%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Recursion Pharmaceuticals NASDAQ:RXRX$6.49 +0.23 (+3.67%) Closing price 04:00 PM EasternExtended Trading$6.51 +0.02 (+0.31%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
